Experienced Leaders. Trusted Governance.

Dr. Chris Beecher is the Founder and Chief Scientific Officer of IROA Technologies, bringing more than 25 years of experience in metabolomics, drug discovery, and life sciences. He earned his Ph.D. in Pharmaceutical Sciences, specializing in Natural Products Chemistry and Biochemistry, from the University of Connecticut and has authored over 75 scientific publications while holding 12 patents.

Throughout his distinguished career, Dr. Beecher has held leadership positions at Ancile Pharmaceuticals, Bristol-Myers Squibb, the University of Illinois at Chicago, Paradigm Genetics, Metabolon, and the University of Michigan. He pioneered the development of the world's first parallel metabolomics platform and later founded the technical foundation of Metabolon, advancing technologies that transformed metabolomics research.

At IROA Technologies, Dr. Beecher leads the continuous development of next-generation metabolomics technologies, data generation platforms, and advanced data interpretation solutions, driving innovation that enables researchers to gain deeper biological insights with greater accuracy and reproducibility.

Adrienne Tymiak is a seasoned scientific executive and strategic advisor with extensive experience in pharmaceutical research, metabolomics, and organizational leadership. She is passionate about leveraging science and technology to create societal impact while fostering innovation, talent development, and collaborative partnerships across academia, industry, and nonprofit organizations.

During her distinguished career at Bristol-Myers Squibb, Adrienne served as Executive Director, leading strategic planning, organizational design, and research initiatives supporting drug discovery and development. She directed multidisciplinary research teams across multiple sites, establishing world-class analytical, bioanalytical, metabolomics, imaging, and informatics capabilities that significantly advanced pharmaceutical research and translational science.

Beyond her corporate leadership, Adrienne mentors emerging innovators, advises technology startups, and contributes to nonprofit organizations focused on education and community impact. She has authored more than 80 scientific publications, book chapters, and patents, delivered over 90 invited presentations, and has served on several scientific and industry boards. As a member of the IROA Technologies Board of Directors, she provides strategic guidance that supports continued scientific innovation and organizational growth.

Gustavo "Gus" Salem is an accomplished life sciences executive with more than 25 years of leadership experience spanning mass spectrometry, analytical instrumentation, diagnostics, and healthcare technologies. He currently serves as President of IDEX Health & Science, where he leads the company's global life science and analytical technologies business.

Prior to joining IDEX, Gus held executive leadership roles as President and Chief Executive Officer of SISCAPA Assay Technologies and Vice President and General Manager of the Biological Systems Division at Agilent Technologies. Throughout his career, he has built and led high-performing organizations focused on scientific innovation, commercial growth, and product development.

With deep expertise in mass spectrometry, analytical instruments, and in vitro diagnostics, Gus brings valuable strategic insight to IROA Technologies. As a member of the Board of Directors, he provides guidance on business strategy, product innovation, and the advancement of metabolomics technologies for both research and clinical applications.

Terry Cross is an accomplished entrepreneur, investor, and business mentor with decades of experience helping technology startups transform innovative ideas into successful companies. Since 2002, he has mentored more than 50 founders across Southeast Michigan and has played a key role in helping entrepreneurs secure over $100 million in investment capital.

Recognized for his leadership in entrepreneurship and venture development, Terry has served in numerous advisory and investment roles with leading organizations, including Invest Michigan, Automation Alley, Ann Arbor Angels, the Michigan Venture Capital Association, and the University of Michigan's Zell Lurie Commercialization Fund. His expertise spans venture funding, technology commercialization, strategic business planning, and innovation ecosystem development.

As a member of the IROA Technologies Board of Directors, Terry provides valuable guidance on corporate strategy, entrepreneurship, investment opportunities, and long-term business growth. His extensive experience supporting emerging technology companies strengthens IROA's mission to advance innovation and expand its global impact in metabolomics and life sciences.

Todd Fink is a seasoned private equity executive and Managing Partner of O2 Investment Partners, bringing more than two decades of experience in mergers and acquisitions, corporate finance, investment strategy, and business growth. Throughout his career, he has led numerous acquisitions, divestitures, joint ventures, and financing transactions across a broad range of industries.

At O2 Investment Partners, Todd is responsible for deal execution, capital allocation, treasury management, and financial strategy. His investment expertise spans manufacturing, chemicals, polymers, automotive, technology, building products, and business services. He also serves on the boards of several portfolio companies, providing strategic oversight and operational guidance that drive long-term value creation.

Prior to joining O2 Investment Partners, Todd was a partner at a leading Detroit-based law firm, where he specialized in corporate law, mergers and acquisitions, real estate, and finance. As a member of the IROA Technologies Board of Directors, he contributes valuable expertise in corporate governance, strategic planning, financial management, and sustainable business growth.